Home >> People >> Faculty
QIN Jun

Ph.D.

Professor, Principal Investigator

Laboratory of Epigenetic Regulation in Tumor Plasticity

Email: qinjun@sibs.ac.cn

Tel: 86-21-54923326

Brief Biography:

2017 - Present Professor, Principal Investigator, Shanghai Institute of Nutrition and Health, CAS

2014 - 2016 Professor, Principal Investigator, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, CAS and Shanghai Jiao Tong University School of Medicine

2012-2014 Assistant Professor, Baylor College of Medicine

2005-2012 Postdoctoral Fellow, Baylor College of Medicine

2000-2005 Ph.D., Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences

 

Research Areas:

The long-term goal of my research will be aimed at elucidating the underlying mechanisms for how epigenetic regulations modulate tumors plasticity with a prime focus on prostate and colorectal cancer. The disease models studied are of high clinical demands. Thus, we believe the knowledge acquired in our studies will lead to the development of alternative therapeutic approaches for cancer prevention and intervention.

1. The underlying mechanism for the indolent tumors transforming into aggressive and metastatic prostate cancer (PCa).

2. During androgen deprivation therapy (ADT), the roles of epigenetic regulations modulate the lineage reprogramming to shift from androgen receptor (AR)-dependent luminal epithelial cells into to neuroendocrine-like cells (NEPC), and thereby lead to the development of castration resistant PCa.

3. How does epigenetic regulation control the malignant transformation of normal stem or progenitor cells into tumor-initiating cells (TICs) in colorectal cancer?

 

Selected Publications: (*Corresponding Author)

  1. Pan Q, Zhong S, Wang H, Wang X, Li N, Li Y, Zhang G, Yuan H, Lian Y, Chen Q, Han Y, Guo J, Liu Q, Qiu T, Jiang J, Li Q, Tan M, Yin H, Peng J*, Xiao Y*, Qin J*. The ZMYND8-regulated Mevalonate Pathway Endows YAP-High Intestinal Cancer with Metabolic Vulnerability. Mol Cell 2021 Apr 22;S1097-2765(21)00314-2. doi: 10.1016/j.molcel.2021.04.009
  2. Qi X, Qiu J, Chang J, Ji Y, Yang Q, Cui G, Sun L, Chai Q, Qin J*, Qiu J*. Brg1 restrains the pro-inflammatory properties of ILC3s and modulates intestinal immunity. Mucosal Immunol 2021 Jan;14(1):38-52
  3. Liu Q, Pang J, Wang LA, Huang Z, Xu J, Yang X, Xie Q, Huang Y, Tang T, Tong D, Liu G, Wang L, Zhang D, Ma Q, Xiao H, Lan W, Qin J*, Jiang J*. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2. J Pathol 2021 Jan;253(1):106-118
  4. Yuan H, Han Y, Wang X, Li N, Liu Q, Yin Y, Wang H, Pan L, Li L, Song K, Qiu T, Pan Q, Chen Q, Zhang G, Zang Y, Tan M, Zhang J, Li Q, Wang X*, Jiang J*, Qin J*. SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways. Cancer Cell 2020 Sep 14;38(3):350-365
  5. Yu T, Gan S, Zhu Q, Dai D, Li N, Wang H, Chen X, Hou D, Wang Y, Pan Q, Xu J, Zhang X, Liu J, Pei S, Peng C, Wu P, Romano S, Mao C, Huang M, Zhu X, Shen K, Qin J*, Xiao Y*. Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24. Nat Commun 2019 Sep 25;10(1):4353
  6. Ding Y, Li N, Dong B, Guo W, Wei H, Chen Q, Yuan H, Han Y, Chang H, Kan S, Wang X, Pan Q, Wu P, Peng C, Qiu T, Li Q, Gao D*, Xue W*, Qin J*. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. J Clin Invest 2019 Feb 1;129(2):759-773
  7. Chen J, Li N, Yin Y, Zheng N, Min M, Lin B, Zhang L, Long X, Zhang Y, Cai Z, Zhai S, Qin J*, Wang X*. Methyltransferase Nsd2 Ensures Germinal Center Selection by Promoting Adhesive Interactions between B Cells and Follicular Dendritic Cells. Cell Rep 2018 Dec 18;25(12):3393-3404
  8. Zhang X, Wang Y, Yuan J, Li N, Pei S, Xu J, Luo X, Mao C, Liu J, Yu T, Gan S, Zheng Q, Liang Y, Guo W, Qiu J, Constantin G, Jin J, Qin J*, Xiao Y*. Macrophage/microglial Ezh2 facilitates autoimmune inflammation through inhibition of Socs3. J Exp Med 2018 May 7;215(5):1365-1382
  9. Yuan H, Li N, Fu D, Ren J, Hui J, Peng J, Liu Y, Qiu T, Jiang M, Pan Q, Han Y, Wang X, Li Q, Qin J*. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis. J Clin Invest 2017 Sep 1;127(9):3375-3391
  10. Li Y, Peng J, Sun T, Li N, Zhang L, Ren J, Yuan H, Kan S, Pan Q, Li X, Ding Y, Jiang M, Cong X, Tan M, Ma Y, Fu D, Cai S, Xiaog Y, Wang X, Qin J*. Epithelial EZH2 serves as an epigenetic determinant in experimental colitis by inhibiting TNFa-mediated inflammation and apoptosis. Proc Natl Acad Sci U S A 2017 May 9;114(19):E3796-E3805
  11. Li N, Xue W, Yuan H, Dong B, Ding Y, Liu Y, Jiang M, Kan S, Sun T, Ren J, Pan Q, Li X, Zhang P, Hu G, Wang Y, Wang X, Li Q, Qin J*. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis. J Clin Invest 2017 Apr;127(4):1284-1302
  12. Qin J*, Lee HJ, Wu SP, Lin SC, Lanz Rb, Creighton CJ, DeMayo FJ, Tsai SY*, Tsai MJ*. Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer. J Clin Invest 2014 Nov;124(11):5013-5026
  13. Qin J, Wu SP, Creighton CJ, Dai F, Xie X, Cheng CM, Frolov A, Ayala G, Lin X, Feng XH, Ittmann M, Tsai SJ, Tsai MJ*, Tsai SY*. COUP-TFII inhibits TGF-b-induced growth barrier to promote prostate Tumorigenesis. Nature 2013 Jan 10;493(7431):236-240